Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 79.4 EUR 1.15% Market Closed
Market Cap: 1.4B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Pharma Mar SA
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharma Mar SA
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Pharma Mar SA
MAD:PHM
Total Liabilities
€151m
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
0%
Grifols SA
MAD:GRF
Total Liabilities
€15.6B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Total Liabilities
€25.1m
CAGR 3-Years
11%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Total Liabilities
€7.7m
CAGR 3-Years
-23%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
No Stocks Found

Pharma Mar SA
Glance View

Market Cap
1.4B EUR
Industry
Biotechnology

Nestled in the vibrant biotech landscape of Spain, Pharma Mar SA emerges as a pioneer, weaving the wonders of the sea into groundbreaking medical therapies. Born from the vision of harnessing marine biodiversity, the company delves into the vast oceanic expanse, unearthing bioactive compounds with potential therapeutic uses. This oceanic pursuit forms the backbone of its innovative approach, focusing on oncological drugs derived from the depths of the sea. Their portfolio showcases significant breakthroughs, with products like Yondelis, originally discovered in a sea squirt, reflecting their unique niche in the drug development pipeline. By advancing these marine-based molecules through intensive clinical research, Pharma Mar translates the ocean's secrets into lifesaving treatments, underscoring its hallmark presence in oncology. The company ingeniously monetizes this frontier exploration by orchestrating a business model encompassing rigorous R&D, strategic partnerships, and licensing agreements. Pharma Mar invests heavily in its research, channeling substantial resources into both preclinical and clinical trials to elevate these marine compounds into market-ready drugs. Partnering with global pharmaceutical heavyweights enables them to extend their market reach while sharing development costs and multiplying revenue streams through royalties and milestone payments. Furthermore, licensing their findings expands their financial foothold, allowing them to reap returns on their intellectual exploits without the burden of full-scale commercialization. Pharma Mar’s adept navigation of the pharmaceutical seas has thus firmly anchored its place within the global biotech arena.

PHM Intrinsic Value
89.32 EUR
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Pharma Mar SA's Total Liabilities?
Total Liabilities
151m EUR

Based on the financial report for Sep 30, 2024, Pharma Mar SA's Total Liabilities amounts to 151m EUR.

What is Pharma Mar SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
0%

Over the last year, the Total Liabilities growth was 5%. The average annual Total Liabilities growth rates for Pharma Mar SA have been -10% over the past three years , 5% over the past five years .

Back to Top